Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24



19391 items
3:42 PM, Sep 21, 2018  |  BioCentury | Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
3:29 PM, Sep 21, 2018  |  BioCentury | Emerging Company Profile

Aprinoia tackles tau

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates. “We are going to develop...
3:23 PM, Sep 21, 2018  |  BioCentury | Finance

Flying Delta in Japan

That Delta-Fly Pharma Inc. is slated to become only the third biotech to go public on Tokyo Stock Exchange’s Mothers in three years is the latest reminder that tough listing standards are still making it...
2:58 PM, Sep 21, 2018  |  BioCentury | Finance

Funding WuXi’s expansion

WuXi AppTec Co. Ltd. (Shanghai:603259) is showing no signs of slowing down. The company is the largest R&D services platform in Asia, and a planned dual listing in Hong Kong that could bring in as...
2:49 PM, Sep 21, 2018  |  BioCentury | Politics, Policy & Law

FDA’s inflection point

Having spent a year at FDA, former Chief Counsel Rebecca Wood sees the agency at an inflection point; it must make dramatic changes in the ways it applies and interprets the law under which it...
2:00 PM, Sep 21, 2018  |  BioCentury | Finance

A bigger ‘biome

With direct-to-consumer products and diagnostics on the market, uBiome Inc. has raised an $83 million series C round to leverage its growing microbiome database and build a therapeutics pipeline. OS Fund led the round, which also...
1:38 PM, Sep 21, 2018  |  BioCentury | Politics, Policy & Law

Filling the rebate void

HHS’s proposal to eliminate drug rebates should have the intended consequence of increasing transparency into drug pricing in the short term. But the long view is that value-based pricing or alternative co-pay agreements will do...
5:53 PM, Sep 14, 2018  |  BioCentury | Politics, Policy & Law

Debating diagnostics

Instead of perpetuating a decades-old dispute about whether FDA can and should regulate laboratory-derived tests, the agency and test makers have moved on to conversations about how FDA should do so, and from threats of...
5:17 PM, Sep 14, 2018  |  BioCentury | Finance

Hua’s institutional advantage

The same market forces that drove Hua Medicine Ltd. to reduce the size of its Hong Kong IPO tempered participation by retail investors, which could help keep the Shanghai diabetes company’s share price steady amidst...
4:48 PM, Sep 14, 2018  |  BioCentury | Finance

Solidifying Atreca’s repertoire

Atreca Inc. parlayed preclinical proof-of-concept data from its antibody platform into a $125 million series C round, which will enable the cancer immunotherapy company to bring its two lead programs into the clinic. An undisclosed,...